Approaches to biomarkers in human colorectal cancer: Looking back, to go forward

Biomarkers in Medicine

Volumn 3, Issue 4, 2009, Pages 385-396

  Nibbe, Rod K ^a   Chance, Mark R ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Cancer; Colon; Genomic; Interaction; Interactomic; Networks; Protein; Proteomic

Indexed keywords

APC PROTEIN; BIOLOGICAL MARKER; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; IRINOTECAN; K RAS PROTEIN; MICRORNA; OXALIPLATIN; PROTEIN P53; SMAD4 PROTEIN; TRANSCRIPTOME; TUMOR MARKER;

BIOPSY; BODY FLUID; CANCER EPIDEMIOLOGY; CANCER GENETICS; CHROMOSOME ABERRATION; COLORECTAL CANCER; COPY NUMBER VARIATION; EPIGENETICS; GENE MUTATION; GENE REGULATORY NETWORK; GENETIC VARIABILITY; GENOME; HUMAN; PHARMACOGENOMICS; PROTEIN INTERACTION; PROTEOMICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 70549110095     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.09.33     Document Type: Review

References (60)

1. Jemal A, Siegel R, Ward E et al.: Cancer statistics. CA Cancer J. Clin. 58, 71-96 (2008).
2. Powell SM, Petersen GM, Krush AJ et al.: Molecular diagnosis of familial adenomatous polyposis. N. Engl. J. Med. 329, 1982-1987 (1993).
3. Markowitz SD, Dawson DM, Willis J, Willson JK: Focus on colon cancer. Cancer Cell 3, 233-236 (2002).
4. Kinzler KW, Vogelstein B: Lessons from hereditary colon cancer. Cell 87, 159-170 (1996).
5. Green RC, Parfrey PS, Woods MO, Younghusband HB: Prediction of Lynch syndrome in consecutive patients with colorectal cancer. J. Natl Cancer Inst. 101, 331-340 (2009).
6. Sawyers CL: The cancer biomarker problem. Nature 452, 548-552 (2008).
7. Hornberg JJ, Bruggeman FJ, Westerhoff HV, Lankelma J: Cancer: a systems biology disease. Biosystems 83, 81-90 (2006).
8. Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat. Med. 10, 789-799 (2004). ■ Good review of the genetic basis for human colorectal cancer, including the relevant downstream signaling pathways, and where the opportunities lie for further research.
9. Calvert PM, Frucht H: The genetics of colorectal cancer. Ann. Intern. Med. 137, 603-612 (2002).
10. Sjöblom T, Jones S, Wood LD et al.: The consensus coding sequences of human breast and colorectal cancers. Science 314, 268-274 (2006). ■■ Landmark paper that identified the driver genes (and passenger genes) implicated in the initiation and/or progression of colorectal cancer (CRC).
11. Saltz LB: Biomarkers in colorectal cancer: added value or just added expense? Expert Rev. Mol. Diagn. 8, 231-233 (2008). ■ Concise and critical review of the state of clinically useful biomarkers in CRC.
12. DeRisi J, Penland L, Brown PO et al.: Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat. Genet. 14, 457-460 (1996). (Pubitemid 26414590)
13. Barrett T, Troup DB, Wilhite SE et al.: NCBI GEO: archive for highthroughput functional genomic data. Nucleic Acids Res. 337(Database issue), D885-D890 (2009).
14. Sabates-Bellver J, Van der Flier LG, de Palo M et al.: Transcriptome profile of human colorectal adenomas. Mol. Cancer Res. 5, 1263-1275 (2007).
15. Jiang X, Tan J, Li J et al.: DACT3 is an epigenetic regulator of Wnt/β-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell 13, 529-541 (2008). (Pubitemid 351766796)
16. Boyer J, Allen WL, McLean EG et al.: Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res. 66, 2765-2777 (2006).
17. Huang DS, Zheng CH: Independent component analysis-based penalized discriminant method for tumor classification using gene expression data. Bioinformatics 22, 1855-1862 (2006).
18. Wang Y, Klijn JG, Zhang Y et al.: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365, 671-679 (2005). (Pubitemid 40260888)
19. van't Veer LJ, Dai H, van de Vijver MJ et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
20. Tsafrir D, Bacolod M, Selvanayagam Z et al.: Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res. 66, 2129-2137 (2006). (Pubitemid 43294922)
21. Chen WD, Han ZJ, Skoletsky J et al.: Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J. Natl Cancer Inst. 97, 1124-1132 (2005). (Pubitemid 41511211)
22. Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233 (2009).
23. Cummins JM, He Y, Leary RJ et al.: The colorectal microRNAome. Proc. Natl Acad. Sci. USA 103, 3687-3692 (2006).
24. Edler D, Glimelius B, Hallstrom M et al.: Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J. Clin. Oncol. 20, 1721-1728 (2002). (Pubitemid 34273259)
25. Soong R, Shah N, Salto-Tellez M et al.: Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann. Oncol. 19, 915-919 (2008). (Pubitemid 351627307)
26. Prall F, Ostwald C, Schiffmann L, Barten M: Do thymidylate synthase gene promoter polymorphism and the C/G single nucleotide polymorphism predict effectiveness of adjuvant 5-fluorouracil-based chemotherapy in stage III colonic adenocarcinoma? Oncol. Rep. 18, 203-209 (2007).
27. Cote JF, Kirzin S, Kramar A et al.: UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin. Cancer Res. 13, 3269-3275 (2007). (Pubitemid 46944912)
28. Amado RG, Wolf M, Peeters M et al.: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26: 1626-1634 (2008).
29. Strimpagos AS, Syrigos KN, Saif, MW: Pharmacogenetics and biomarkers in colorectal cancer. Pharmacogenomics J. 9, 147-160 (2009).
30. Turner N, Tutt A, Ashworth A: Hallmarks of 'BRCAness' in sporadic cancers. Nat. Rev. Cancer 4, 814-819 (2004).
31. Jansen R, Greenbaum D, Gerstein M: Relating whole-genome expression data with protein-protein interactions. Genome Res. 12, 37-46 (2002). (Pubitemid 34065588)
32. Cox J, Mann M: MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367-1372 (2008).
33. Service RF: Proteomics ponders prime time. Science 321, 1758-1761 (2008). ■ Adequately covers the challenges facing the proteomics community in identifying biomarkers in human disease.
34. Kaaks R, Toniolo P, Akhmedkhanov A et al.: Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J. Natl Cancer Inst. 92, 1592-1600 (2000). (Pubitemid 30770509)
35. Ward DG, Suggett N, Cheng Y et al.: Identification of serum biomarkers for colon cancer by proteomic analysis. Br. J. Cancer 94, 898-905 (2006).
36. Habermann JK, Paulsen U, Roblick UJ et al.: Stage-specific alterations of the genome, transcriptome, and proteome during colorectal carcinogenesis. Genes Chromosomes Cancer 46, 10-26 (2007). (Pubitemid 44772868)
37. Chen YD, Zheng S, Yu JK et al.: Artificial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population. Clin. Cancer Res. 10, 8380-8385 (2004). (Pubitemid 40053400)
38. Aggarwal K, Choe LH, Lee KH: Shotgun proteomics using the iTRAQ isobaric tags. Brief. Funct. Genomic. Proteomic. 5, 112-120 (2006). (Pubitemid 46403004)
39. Asara JM, Christofk HR, Freimark LM et al.: A label-free quantification method by MS/MS TIC compared with SILAC and spectral counting in a proteomics screen. Proteomics 8, 994-999 (2008).
40. Gafken PR, Lampe PD: Methodologies for characterizing phosphoproteins by mass spectrometry. Cell Commun. Adhes. 13, 249-262 (2006).
41. Hanash SM, Pitteri SJ, Faca VM: Mining the plasma proteome for cancer biomarkers. Nature 452, 571-579 (2008).
42. Friedman DB, Hill S, Keller JW et al.: Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 4, 793-811 (2004). (Pubitemid 38339157)
43. Alfonso P, Núñez A, Madoz-Gurpide J et al.: Proteomic expression analysis of colorectal cancer by two-dimensional differential gel electrophoresis. Proteomics 5, 2602-2611 (2005). (Pubitemid 40966487)
44. Mazzanti R, Solazzo M, Fantappié O et al.: Differential expression proteomics of human colon cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 290, 1329-1338 (2006).
45. Ong SE, Foster LJ, Mann M: Mass spectrometric-based approaches in quantitative proteomics. Methods 29, 124-130 (2003).
46. Kim JE, Tannenbaum SR, White FM: Global phosphoproteome of HT-29 human colon adenocarcinoma cells. J. Proteome Res. 4, 1339-1346 (2005).
47. Volmer MW, Stühler K, Zapatka M et al.: Differential proteome analysis of conditioned media to detect Smad4 regulated secreted biomarkers in colon cancer. Proteomics 5, 2587-2601 (2005). (Pubitemid 40966486)
48. Yu J, Shannon WD, Watson MA et al.: Gene expression profiling of the irinotecan pathway in colorectal cancer. Clin. Cancer Res. 11, 2053-2062 (2005). (Pubitemid 40471872)
49. McMurray HR, Sampson ER, Compitello G et al.: Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype. Nature 453, 1112-1116 (2008). (Pubitemid 351871734)
50. Boone C, Bussey H, Andrews BJ: Exploring genetic interactions and networks with yeast. Nat. Rev. Genet. 8, 437-439 (2008).
51. De Las Rivas J, de Luis A: Interactome data and databases: different types of protein interaction. Comp. Funct. Genomics 5, 173-178 (2004). (Pubitemid 38744654)
52. Mathivanan S, Periaswamy B, Gandhi TK et al.: An evaluation of human protein-protein interaction data in the public domain. BMC Bioinformatics 7(Suppl. 5) S19 (2006).
53. Chuang HY, Lee E, Liu YT et al.: Network-based classification of breast cancer metastasis. Mol. Syst. Biol. 3, 140-150 (2007). ■■ Widely influential paper that showed network-based markers of breast cancer were more accurate classifiers of metastatic breast cancer, compared with a traditional microarray approach.
54. Jonsson PF, Bates PA: Global topological features of cancer proteins in the human interactome. Bioinformatics 22, 2291-2297 (2007).
55. Segal E, Friedman N, Koller D et al.: A module map showing conditional activity of expression modules in cancer. Nat. Genet. 36, 1090-1098 (2004). (Pubitemid 41184471)
56. Nibbe RK, Markowitz S, Myeroff L et al.: Discovery and scoring of protein interaction subnetworks discriminative of late stage human colon cancer. Mol. Cell. Proteomics 8, 827-845 (2009). ■ Describes a novel 'proteomics-first' approach to identify protein subnetworks discriminative of late-stage CRC versus control, which provide mechanistic models for hypothesis testing in vivo.
57. Lynch syndrome: Bethesda (MD). National Library of Medicine (USA), Specialized Information Services Division (2003; reviewed 2008). http://chem.sis.nlm.nih.gov/chemidplus/ chemidlite.jsp
58. American Cancer Society (2008). www.cancer.org/docroot/cri/content/ cri-2-4-1x-what-are-the-key-statistics- for-colon-and-rectum-cancer.asp
59. Human Proteome Initiative (2008). http://ca.expasy.org/sprot/hpi
60. National Cancer Institute: VisualsOnline. http://visualsonline.cancer. gov/details. cfm?imageid=7181